EP2819516
USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
:
EP einkaleyfi: Þýðing ekki lögð inn:
27.7.2012:
25.12.2019:
12820058.1
:
26.7.2032
:
USE OF (1R,5S)-(+)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO{3.1.0}HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS
27.7.2012
25.12.2019
:
Otsuka America Pharmaceutical, Inc.:
2440 Research Boulevard, Rockville, MD 20850, US
:
MCKINNEY, Anthony Alexander:
Newton Center, MA 02459, US
:
BYMASTER, Frank:
Brownsburg, IN 46112, US
:
201161574231 P:
30.7.2011:
US
:
201113334066:
22.12.2011:
US
:
201213528940:
21.6.2012:
US
:
US2012000335:
27.7.2012
:
A61K 9/00, A61P 25/00, A61K 31/403